<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>C1 inhibitor, recombinant human: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">C1 inhibitor, recombinant human: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">C1 inhibitor, recombinant human: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="96480" href="/d/html/96480.html" rel="external">see "C1 inhibitor, recombinant human: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="127035" href="/d/html/127035.html" rel="external">see "C1 inhibitor, recombinant human: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F25819120"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ruconest</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F25320498"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        C1 Esterase Inhibitor;</li>
<li>
                        Complement Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F26080356"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6fdac7f-1466-435d-8ceb-b7b28141de63">Hereditary angioedema attacks, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema attacks, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>To minimize morbidity and mortality, should be self-administered (or administered by a caregiver) at the onset of an attack whenever possible (US HAEA [Busse 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight &lt;84 kg</i>: 50 units/kg as a single dose; some experts recommend rounding up the dose to utilize a full vial (2,100 units/vial); maximum single dose: 4,200 units (Zuraw 2022; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight ≥84 kg</i>: 4,200 units as a single dose (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Repeat dosing</i>: A clinical response is usually observed within ~2 to 4 hours of the initial dose; after ~2 to 4 hours, a second dose may be given if symptoms worsen, but this is rarely needed; no more than 2 doses may be administered per 24 hours, maximum daily dose: 8,400 units/day (Zuraw 2010; Zuraw 2022; manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c79c3f5-90ab-4be5-9a10-e2f295a89aae">Hereditary angioedema attacks, long-term prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema attacks, long-term prophylaxis (off-label use) (alternative agent):</b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight &lt;84 kg:</i> 50 units/kg (maximum dose: 4,200 units) twice weekly (Riedl 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight ≥84 kg:</i> 4,200 units twice weekly (Riedl 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May reduce frequency of administration to once weekly, ensuring maintenance of symptom control; once-weekly dosing was shown to be more effective than placebo but with the potential for more frequent attacks compared with twice-weekly dosing (Reshef 2013, Riedl 2017). Dosing more than twice weekly has not been studied.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990918"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988211"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F26080357"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F26080355"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="127035" href="/d/html/127035.html" rel="external">see "C1 inhibitor, recombinant human: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a39710ed-d7c6-4808-9b5f-163ad50ecca1">Hereditary angioedema, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema (HAE), prophylaxis:</b> Limited data available (Riedl 2017):</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥13 years:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;84 kg: IV: 50 units/kg twice weekly; maximum dose: 4,200 units/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">≥84 kg: IV: 4,200 units twice weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dosing based on a small multinational phase II randomized double-blind placebo-controlled crossover trial in patients with frequent attacks (defined as a history of ≥4 HAE attacks per month for ≥3 consecutive months) and C1 inhibitor levels &lt;50% of normal. Both weekly and twice-weekly administration of C1 inhibitor (recombinant) significantly reduced the number of HAE attacks after 4 weeks of therapy compared with placebo; however, the twice-weekly regimen resulted in more consistent achievement of ≥50% reduction in attacks (Riedl 2017). May reduce frequency of administration to once weekly, ensuring maintenance of symptom control; once-weekly dosing was shown to be more effective than placebo but with the potential for more frequent attacks compared with twice-weekly dosing (Reshef 2013; Riedl 2017).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1f71a07-b979-45b6-b936-a325253cfed2">Hereditary angioedema, treatment of acute attacks</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema (HAE), treatment of acute attacks (non-laryngeal):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years: Limited data available: IV: 50 units/kg as a single dose, maximum dose: 4,200 units/dose. Dosing based on a small open-label phase II multinational study (n=20 subjects accounting for 73 HAE attacks; age range: 5 to 14 years); approximately 96% (70/73) HAE attacks were treated with a single dose; time to beginning of symptom relief occurred in a median of 60 minutes and time to minimal symptoms occurred in a median of 122.5 minutes; instances of multiple doses included: 1 patient received a second dose during 1 attack and another received a second dose during 2 separate attacks for persistent symptoms; treatment was well-tolerated overall (Reshef 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: <b>Note:</b> Unlike human C1 inhibitors, efficacy not established in patients with laryngeal attacks due to a limited number of patients; in some trials, patients with laryngeal attacks were excluded (Valerieva 2018; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;84 kg: IV: 50 units/kg as a single dose, maximum dose: 4,200 units/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">≥84 kg: IV: 4,200 units as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Redosing: If attack symptoms persist, 1 additional dose may be administered; no more than 2 doses may be administered per 24 hours. In trials, patients were administered a second dose 4 hours after the initial dose if relief not achieved; median time to minimal symptoms was about 5 hours (range: 4 to 12 hours) (Riedl 2014).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090233"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51090234"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F26188914"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Immunologic: Antibody development (6% to ≤17%; anti-C1INH, anti-rhC1INH, and anti-host-related impurities)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (10%; includes procedural headache), vertigo (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Burning sensation of skin (2%), erythema (2%; marginatum)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (≥2%), nausea (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: C-reactive protein increased (2%), increased serum fibrinogen (fibrin D-dimer: 2%), lipoma (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sneezing (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Abdominal pain, anaphylaxis, skin rash</p></div>
<div class="block coi drugH1Div" id="F25320510"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor preparations or any component of the formulation; allergy to rabbits or rabbit-derived products. <b>Note:</b> Patients with a clinical history of a rabbit allergy and/or cow's milk allergy who are negative on skin testing to C1 inhibitor (recombinant) have tolerated a subcutaneous challenge of C1 inhibitor (recombinant) (van den Elzen 2016).</p></div>
<div class="block war drugH1Div" id="F26080342"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe hypersensitivity reactions (eg, urticaria, hives, tightness of the chest, wheezing, hypotension, anaphylaxis) may occur during or after administration. Signs/symptoms of hypersensitivity reactions may be similar to the attacks associated with hereditary angioedema, therefore, consideration should be given to treatment methods. In the event of acute hypersensitivity reactions to C1 inhibitor therapy, treatment should be discontinued and appropriate treatment should be instituted. </p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic events: Serious arterial and venous thromboembolic events have been reported at recommended doses in patients with risk factors (eg, presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, immobility). Closely monitor patients with preexisting risks for thrombotic events during and after administration. </p></div>
<div class="block foc drugH1Div" id="F25819121"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ruconest: 2100 units (1 ea) [contains rabbit protein]</p></div>
<div class="block geq drugH1Div" id="F25819119"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26116580"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Ruconest Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2100 unit (per each): $9,150.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F26080361"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer by a separate infusion line as a slow IV injection over ~5 minutes. Appropriately trained patients may self-administer upon recognition of an HAE attack.</p></div>
<div class="block admp drugH1Div" id="F52620162"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Administer through a separate infusion line as a slow IV injection over ~5 minutes. Appropriately trained patients may self-administer upon recognition of a hereditary angioedema (HAE) attack. In pediatric treatment trials for HAE, doses in children ≤12 years of age were administered over 5 minutes (Reshef 2019).</p></div>
<div class="block use drugH1Div" id="F25320500"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema attacks, treatment:</b> Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Effectiveness not established in HAE patients with laryngeal attacks.</p></div>
<div class="block off-label drugH1Div" id="F50906898"><span class="drugH1">Use: Off-Label: Adult</span><p>Hereditary angioedema attacks, long-term prophylaxis</p></div>
<div class="block cyt drugH1Div" id="F25498144"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F25498141"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the thrombogenic effect of C1 inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May enhance the thrombogenic effect of C1 inhibitors.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F26080339"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following maternal administration of C1 inhibitor (recombinant) for the treatment of hereditary angioedema (HAE) attacks during pregnancy are limited (Grivcheva-Panovska 2020; Hakl 2018; Moldovan 2019). In one case, treatment of the mother may have also resolved an attack in the fetus (Grivcheva-Panovska 2020).</p>
<p style="text-indent:0em;margin-top:2em;">C1 inhibitor (human) is preferred for the treatment and prophylaxis of HAE during pregnancy. Patients with HAE should be monitored closely during pregnancy and for at least 72 hours after delivery (WAO/EAACI [Maurer 2022]).</p></div>
<div class="block brc drugH1Div" id="F26080341"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if C1 Inhibitor (recombinant) is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Lactation may increase the frequency of hereditary angioedema (HAE) attacks; patients with HAE should be monitored closely. Recommendations between guidelines vary; however, C1 inhibitor (recombinant) may be used for the treatment and prophylaxis of HAE during lactation (US HAEA [Busse 2021]; WAO/EAACI [Maurer 2022]).</p></div>
<div class="block mop drugH1Div" id="F26080363"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs/symptoms of hypersensitivity reactions and thrombotic events. Prior to initiation for long-term prophylaxis, test for immunoglobulin E (IgE) antibodies against rabbit antigens; repeat testing annually or after 10 treatments, whichever occurs first (WAO [Craig 2012]).</p></div>
<div class="block pha drugH1Div" id="F26080347"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">C1 inhibitor, a serine protease inhibitor (serpin), regulates the activation of the complement and contact system pathways by irreversibly binding target proteases. Suppression of contact system activation by C1 inhibitor through the inactivation of plasma kallikrein and factor XIIa is thought to modulate vascular permeability that leads to clinical manifestations of hereditary angioedema (HAE) attacks by preventing the generation of bradykinin.</p></div>
<div class="block phk drugH1Div" id="F26080349"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Onset of symptom relief: Median: 90 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>: ~3 L</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~2.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~0.3 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F25745601"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ruconest</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32898710">
<a name="32898710"></a>Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. <i>J Allergy Clin Immunol Pract</i>. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/32898710/pubmed" id="32898710" target="_blank">32898710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23282420">
<a name="23282420"></a>Craig T, Aygören-Pürsün E, Bork K, et al. WAO guideline for the management of hereditary angioedema. <i>World Allergy Organ J</i>. 2012;5(12):182-199. doi: 10.1097/WOX.0b013e318279affa.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/23282420/pubmed" id="23282420" target="_blank">23282420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33083708">
<a name="33083708"></a>Grivcheva-Panovska V, Giannetti B. Hereditary Angioedema attack in utero and treatment of the mother and fetus. <i>Mayo Clin Proc Innov Qual Outcomes</i>. 2020;4(5):595-600. doi:10.1016/j.mayocpiqo.2020.06.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/33083708/pubmed" id="33083708" target="_blank">33083708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30280305">
<a name="30280305"></a>Hakl R, Kuklínek P, Krčmová I, et al. Treatment of hereditary angioedema attacks with icatibant and recombinant C1 inhibitor during Ppegnancy. <i>J Clin Immunol.</i> 2018;38(7):810-815. doi:10.1007/s10875-018-0553-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/30280305/pubmed" id="30280305" target="_blank">30280305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29594115">
<a name="29594115"></a>Longhurst H. Optimum use of acute treatments for hereditary angioedema: evidence-based expert consensus. <i>Front Med (Lausanne)</i>. 2018;4:245. doi: 10.3389/fmed.2017.00245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/29594115/pubmed" id="29594115" target="_blank">29594115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29318628">
<a name="29318628"></a>Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema: the 2017 revision and update [published online January 10, 2018]. <i>Allergy</i>. doi: 10.1111/all.13384.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/29318628/pubmed" id="29318628" target="_blank">29318628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35497649">
<a name="35497649"></a>Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update.<i> World Allergy Organ J</i>. 2022;15(3):100627. doi:10.1016/j.waojou.2022.100627<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/35497649/pubmed" id="35497649" target="_blank">35497649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31170541">
<a name="31170541"></a>Moldovan D, Bernstein JA, Hakl R, et al. Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy. <i>J Allergy Clin Immunol Pract.</i> 2019;7(8):2938-2940. doi:10.1016/j.jaip.2019.05.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/31170541/pubmed" id="31170541" target="_blank">31170541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30993784">
<a name="30993784"></a>Reshef A, Grivcheva-Panovska V, Kessel A, et al. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. <i>Pediatr Allergy Immunol</i>. 2019;30(5):562-568.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/30993784/pubmed" id="30993784" target="_blank">30993784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23121116">
<a name="23121116"></a>Reshef A, Moldovan D, Obtulowicz K, et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. <i>Allergy</i>. 2013;68(1):118-124. doi: 10.1111/all.12060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/23121116/pubmed" id="23121116" target="_blank">23121116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24468257">
<a name="24468257"></a>Riedl MA, Bernstein JA, Li H, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. <i>Ann Allergy Asthma Immunol</i>. 2014;112(2):163-169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/24468257/pubmed" id="24468257" target="_blank">24468257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28754491">
<a name="28754491"></a>Riedl MA, Grivcheva-Panovska V, Moldovan D, et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. <i>Lancet</i>. 2017;390(10102):1595-1602. doi: 10.1016/S0140-6736(17)31963-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/28754491/pubmed" id="28754491" target="_blank">28754491</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ruconest (C1 esterase inhibitor [recombinant]) [prescribing information]. Warren, NJ: Pharming Healthcare Inc; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30021471">
<a name="30021471"></a>Valerieva A, Caccia S, Cicardi M. Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema. <i>Expert Rev Clin Immunol</i>. 2018;14(9):707-718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/30021471/pubmed" id="30021471" target="_blank">30021471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27321437">
<a name="27321437"></a>van den Elzen MT, van Os-Medendorp H, Röckmann-Helmbach H, et al. Allergenicity and safety of recombinant human C1 esterase inhibitor in patients with allergy to rabbit or cow's milk. <i>J Allergy Clin Immunol</i>. 2016;138(2):476-481. doi: 10.1016/j.jaci.2016.04.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/27321437/pubmed" id="27321437" target="_blank">27321437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zuraw.1">
<a name="Zuraw.1"></a>Zuraw B, Farkas H. Hereditary angioedema: acute treatment of angioedema attacks. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20920772">
<a name="20920772"></a>Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. <i>J Allergy Clin Immunol</i>. 2010;126(4):821-827.e14. doi:10.1016/j.jaci.2010.07.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-recombinant-human-drug-information/abstract-text/20920772/pubmed" id="20920772" target="_blank">20920772</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 96337 Version 94.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
